Details for Patent: 10,888,547
✉ Email this page to a colleague
Which drugs does patent 10,888,547 protect, and when does it expire?
Patent 10,888,547 protects CERDELGA and is included in one NDA.
This patent has one hundred and eight patent family members in forty countries.
Summary for Patent: 10,888,547
| Title: | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| Abstract: | The hemitartrate salt of a compound represented by the following structural formula: ##STR00001## (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. |
| Inventor(s): | Peterschmitt; Judith (Watertown, MA) |
| Assignee: | Genzyme Corporation (Cambridge, MA) |
| Application Number: | 15/049,946 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,888,547
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE) | ⤷ Try a Trial | |||
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY) | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,888,547
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 079152 | ⤷ Try a Trial | |||
| Argentina | 121611 | ⤷ Try a Trial | |||
| Argentina | 121612 | ⤷ Try a Trial | |||
| Australia | 2010324810 | ⤷ Try a Trial | |||
| Australia | 2016202591 | ⤷ Try a Trial | |||
| Australia | 2017265180 | ⤷ Try a Trial | |||
| Brazil | 112012012947 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
